
Keywords: AD; Alzheimer's disease; AGEs; advanced glycation end products; BBB; blood-brain barrier; BDNF; brain-derived nerve growth factor; CML; carboxymethyllysine; CMRg; cerebral metabolic rate of glucose; DAMPs; damage-associated molecular patterns; GLUT; gluco